NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
VTRS
Viatris Inc.
VTRS has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VTRS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
VTRS's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VTRS PE Valuation
VTRS has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VTRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
VTRS has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over VTRS on earnings quality, reporting a profit while its opponent remains loss making.
VTRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.65 | — |
| Q3 2026 | -$0.57 | +$2.52 |
| Q2 2026 | -$0.40 | +$2.50 |
| Q1 2026 | -$0.30 | +$2.87 |
| Q4 2025 | -$3.00 | -$2.47 |
| Q3 2025 | -$3.09 | -$2.36 |
| Q2 2025 | -$2.90 | -$2.36 |
| Q1 2025 | -$3.17 | -$3.12 |
| Q4 2024 | -$0.53 | -1160% |
VTRS is still losing money, but far less than before: $0.57 per share over the past year, against $3.17 at its worst in early 2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over VTRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over VTRS on profitability, with a higher operating margin.
VTRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | -0.3% |
| Q2 2026 | $3.8B | +4.9% |
| Q1 2026 | $3.5B | +8.1% |
| Q4 2025 | $3.7B | +5% |
| Q3 2025 | $3.8B | +0.2% |
| Q2 2025 | $3.6B | -5.6% |
| Q1 2025 | $3.3B | -11% |
| Q4 2024 | $3.5B | -8.1% |
VTRS's revenue is growing: $3.7B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +2.2 points |
| Q2 2026 | 0.2% | -6.3 points |
| Q1 2026 | -2.3% | +86 points |
| Q4 2025 | -5.2% | -0.1 points |
| Q3 2025 | 4.8% | -1.3 points |
| Q2 2025 | 6.5% | +13 points |
| Q1 2025 | -89% | -94 points |
| Q4 2024 | -5.1% | +6.7 points |
VTRS's operating margin was 7% last quarter, up 2.2 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over VTRS on cash flow, with more consistent year-over-year improvement.
VTRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $813.7M | +24% |
| Q2 2026 | $329M | +97% |
| Q1 2026 | $348.4M | -29% |
| Q4 2025 | $619.3M | +81% |
| Q3 2025 | $658.1M | -12% |
| Q2 2025 | $166.8M | -48% |
| Q1 2025 | $492.9M | -13% |
| Q4 2024 | $342.3M | +9% |
VTRS generated $2.1B in free cash flow over the past year, up 27% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
VTRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -14.7M shares |
| 1 year | -1.4% | -16M shares |
| 3 years | -4.3% | -51.1M shares |
| 5 years | -5.3% | -64M shares |
VTRS has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150M |
| Q2 2026 | $150M |
| Q1 2026 | — |
| Q4 2025 | $85.1M |
| Q3 2025 | $67.9M |
| Q2 2025 | $175M |
| Q1 2025 | $175.4M |
| Q4 2024 | — |
VTRS spent $385M buying back its own shares over the past year, down 7.9% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over VTRS on leverage, with a lower net debt burden relative to earnings.
VTRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.1x | High |
| Q2 2026 | 4.6x | High |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 96.8x | High |
| Q3 2025 | 105.5x | High |
| Q2 2025 | 89.2x | High |
| Q4 2024 | 4.6x | High |
| Q3 2024 | 5.5x | High |
VTRS's net debt is about 4.1 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VTRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.1 | Overbought |
| Stochastic | 92.0 | Overbought |
VTRS's weekly RSI is 73 (overbought) and its Stochastic is 92 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VTRS PE vs Healthcare Sector
| Metric | VTRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VTRS has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
VTRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.7 | 11% above |
| 20 week MA | $17.5 | 18% above |
| 50 week MA | $15.6 | 33% above |
| 100 week MA | $12.7 | 63% above |
| 200 week MA | $11.8 | 75% above |
VTRS has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
VTRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.7 | $17.8 | -9.9% |
| 2021 | $17.8 | $13.6 | -23% |
| 2022 | $13.6 | $11.0 | -19% |
| 2023 | $11.0 | $10.8 | -1.6% |
| 2024 | $10.8 | $12.5 | +15% |
| 2025 | $12.5 | $12.3 | -1.3% |
| 2026 YTD | $12.3 | $20.7 | +68% |
VTRS has the edge over NVO on returns for 2026, with the stronger performance.